HIV阳性实体器官移植受者的免疫抑制药物管理

邵琨; 王祥慧; 周佩军

doi:10.3969/j.issn.1674-7445.2024009

HIV阳性实体器官移植受者的免疫抑制药物管理

doi: 10.3969/j.issn.1674-7445.2024009

邵琨^{1, 2, ,},
王祥慧^{1, 2},
周佩军^{1, 2}

1.
200025　上海，上海交通大学医学院附属瑞金医院泌尿科
2.
上海交通大学医学院附属瑞金海南医院国际移植医疗康复诊疗中心

基金项目: 海南省卫生健康行业科研项目（22A200345）

详细信息

通讯作者:
邵琨（ORCID 0000-0001-5196-4529），Email：shaokunrj@163.com

中图分类号: R617, R373
计量
- 文章访问数: 52
- HTML全文浏览量: 28
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2024-01-26
- 网络出版日期: 2024-04-29
- 刊出日期: 2024-07-15

Management of immunosuppressive drugs in HIV-positive solid organ transplant recipients

Shao Kun^{1, 2
, ,},
Wang Xianghui^{1, 2},
Zhou Peijun^{1, 2}

1.
Depatrment of Urology, Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai 200025, China

More Information

Corresponding author: Shao Kun, Email: shaokunrj@163.com

摘要

摘要: 联合抗逆转录病毒治疗（cART）的应用显著提高了人类免疫缺陷病毒（HIV）感染者的预期寿命。但病毒感染和cART药物的不良反应使患者更容易发生器官衰竭。针对HIV感染者的终末期器官衰竭患者，实体器官移植成为一种标准的治疗方案。然而，在HIV阳性实体器官移植受者中，存在移植物排斥反应发生增多、感染风险升高、药物毒性以及cART治疗和免疫抑制药之间的药物相互作用等诸多问题，管理HIV阳性实体器官移植受者具有极大的挑战性。因此，本文就免疫诱导治疗、钙调磷酸酶抑制剂、哺乳动物雷帕霉素靶蛋白抑制剂及其他免疫抑制药在HIV阳性实体器官移植受者中的应用进行综述，旨在为未来 HIV 阳性实体器官移植受者的免疫抑制管理提供参考。
- 人类免疫缺陷病毒 /
- 实体器官移植 /
- 联合抗逆转录病毒治疗 /
- 免疫诱导 /
- 钙调磷酸酶抑制剂 /
- 哺乳动物雷帕霉素靶蛋白抑制剂 /
- 霉酚酸 /
- 糖皮质激素
Abstract: The application of combination antiretroviral therapy (cART) has significantly prolonged the life expectancy of patients infected with human immunodeficiency virus (HIV). However, viral infection and adverse reactions of cART drugs make patients more prone to organ failure. Solid organ transplantation has become a standard treatment for HIV-infected patients with end-stage organ failure. Nevertheless, among HIV-positive soild organ transplant recipients, multiple problems remain to be resolved, such as increased incidence of graft rejection, increased infection risk, drug toxicity and drug interaction between cART therapy and immunosuppressive drugs, etc. It is extremely challenging to deliver appropriate management for HIV-positive soild organ transplant recipients. Therefore, the application of immune induction therapy, calcineurin inhibitors, mammalian target of rapamycin (mTOR) inhibitors and other immunosuppressive drugs in HIV-positive soild organ transplant recipients was reviewed, aiming to provide reference for subsequent management of immunosuppression in HIV-positive soild organ transplant recipients.
- Human immunodeficiency virus /
- Solid organ transplantation /
- Combination antiretroviral therapy /
- Immune induction /
- Calcineurin inhibitor /
- Mammalian target of rapamycin inhibitor /
- Mycophenolic acid /
- Glucocorticoid

HTML全文

FIG. 3253. FIG. 3253.

FIG. 3253.. FIG. 3253.

下载: 全尺寸图片幻灯片

参考文献(39)

[1]	The path that ends AIDS: UNAIDS Global AIDS Update 2023[EB/OL]. [2024-01-07].https://www.unaids.org/sites/default/files/media_asset/2023-unaids-global-aids-update_en.pdf.
[2]	芦佳骏, 费发珠, 任宾. HIV感染者非酒精性脂肪性肝病的临床研究进展[J]. 临床肝胆病杂志, 2023, 39(6): 1446-1453. DOI: 10.3969/j.issn.1001-5256.2023.06.030. LU JJ, FEI FZ, REN B. Research advances in nonalcoholic fatty liver disease in individuals with HIV infection[J]. J Clin Hepatol, 2023, 39(6): 1446-1453. DOI: 10.3969/j.issn.1001-5256.2023.06.030.
[3]	邵莉, 陈继军, 包凯, 等. 基于贝叶斯Cox风险比例回归的兰州市HIV感染者/AIDS患者死亡影响因素分析[J]. 中山大学学报(医学科学版), 2023, 44(2): 224-231. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0206. SHAO L, CHEN JJ, BAO K, et al. Influencing factors of HIV/ AIDS death based on Bayesian Cox proportional hazard regression model[J]. J Sun Yat-sen Univ (Med Sci), 2023, 44(2): 224-231. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0206.
[4]	POURNAMDARI AB, HSUE PY, PARIKH RV. HIV-associated cardiovascular disease: beyond the macrovascular[J]. J Am Heart Assoc, 2023, 12(22): e031876. DOI: 10.1161/JAHA.123.031876.
[5]	CERVANTES CE, ATTA MG. Updates on HIV and kidney disease[J]. Curr HIV/AIDS Rep, 2023, 20(2): 100-110. DOI: 10.1007/s11904-023-00645-1.
[6]	NAVARRO J. HIV and liver disease[J]. AIDS Rev, 2022, 25(2): 87-96. DOI: 10.24875/AIDSRev.M22000052.
[7]	STOCK PG, BARIN B, MURPHY B, et al. Outcomes of kidney transplantation in HIV-infected recipients[J]. N Engl J Med, 2010, 363(21): 2004-2014. DOI: 10.1056/NEJMoa1001197.
[8]	COFFIN CS, STOCK PG, DOVE LM, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients[J]. Am J Transplant, 2010, 10(5): 1268-1275. DOI: 10.1111/j.1600-6143.2010.03070.x.
[9]	KUMAR RN, STOSOR V. Advances in liver transplantation for persons with human immunodeficiency infection[J]. Curr Infect Dis Rep, 2022, 24(3): 39-50. DOI: 10.1007/s11908-022-00776-3.
[10]	郑鑫, 胡小鹏, 薛文瑞, 等. HIV阳性患者接受亲属活体供肾移植一例及文献复习[J]. 中华器官移植杂志, 2019, 40(2): 88-91. DOI: 10.3760/cma.j.issn.0254-1785.2019.02.006. ZHENG X, HU XP, XUE WR, et al. HIV-positive patient receiving living related renal transplantation: a report of one case and literature review[J]. Chin J Organ Transplant, 2019, 40(2): 88-91. DOI: 10.3760/cma.j.issn.0254-1785.2019.02.006.
[11]	冯文霞, 董常峰, 冯程, 等. 超声在HIV感染合并乙型病毒性肝炎肝硬化患者肝移植中的应用[J/OL]. 新发传染病电子杂志, 2021, 6(4): 294-297. DOI: 10.19871/j.cnki.xfcrbzz.2021.04.006. FENG WX, DONG CF, FENG C, et al. Ultrasound application in liver transplantation for HIV-infected patients with concomitant hepatitis B virus-related liver cirrhosis[J/OL]. Electr J Emerg Infect Dis, 2021, 6(4): 294-297. DOI: 10.19871/j.cnki.xfcrbzz.2021.04.006
[12]	赖宇婷, 赵宁波, 董常峰, 等. 超声对HIV感染患者肾移植术后的诊治分析[J]. 罕少疾病杂志, 2023, 30(6): 38-40. DOI: 10.3969/j.issn.1009-3257.2023.06.017. LAI YT, ZHAO NB, DONG CF, et al. Analysis of diagnosis and treatment for HIV-infected patients after kidney transplantation with ultrasound[J]. J Rare Uncommon Dis, 2023, 30(6): 38-40. DOI: 10.3969/j.issn.1009-3257.2023.06.017.
[13]	Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS). Organ procurement and transplantation: implementation of the HIV Organ Policy Equity act. final rule[J]. Fed Regist, 2015, 80(89): 26464-26467.
[14]	LAGOUTTE-RENOSI J, FLAMMANG M, DUCLOUX D, et al. Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants[J]. J Chemother, 2022, 34(3): 199-202. DOI: 10.1080/1120009X.2021.1940436.
[15]	ALMANGOUR TA, SKERSICK PT, CORBETT A, et al. Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report[J]. AIDS Res Ther, 2023, 20(1): 55. DOI: 10.1186/s12981-023-00551-x.
[16]	MCCAIN JD, CHASCSA DM. Special considerations in the management of HIV and viral hepatitis coinfections in liver transplantation[J]. Hepat Med, 2022, 14: 27-36. DOI: 10.2147/HMER.S282662.
[17]	CARTER JT, MELCHER ML, CARLSON LL, et al. Thymoglobulin-associated CD4⁺ T-cell depletion and infection risk in HIV-infected renal transplant recipients[J]. Am J Transplant, 2006, 6(4): 753-760. DOI: 10.1111/j.1600-6143.2006.01238.x.
[18]	FERNÁNDEZ-RUIZ M, LÓPEZ-MEDRANO F, ALLENDE LM, et al. Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation[J]. Transpl Int, 2014, 27(7): 674-685. DOI: 10.1111/tri.12321.
[19]	ROLAND ME, BARIN B, HUPRIKAR S, et al. Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls[J]. AIDS, 2016, 30(3): 435-444. DOI: 10.1097/QAD.0000000000000934.
[20]	KUCIRKA LM, DURAND CM, BAE S, et al. Induction immunosuppression and clinical outcomes in kidney transplant recipients infected with human immunodeficiency virus[J]. Am J Transplant, 2016, 16(8): 2368-2376. DOI: 10.1111/ajt.13840.
[21]	LYNCH EN, RUSSO FP. Liver transplantation in people living with HIV: still an experimental procedure or standard of care?[J]. Life (Basel), 2023, 13(10): 1975. DOI: 10.3390/life13101975.
[22]	KOVAL CE, FARR M, KRISL J, et al. Heart or lung transplant outcomes in HIV-infected recipients[J]. J Heart Lung Transplant, 2019, 38(12): 1296-1305. DOI: 10.1016/j.healun.2019.09.011.
[23]	DOBERNE JW, JAWITZ OK, RAMAN V, et al. Heart transplantation survival outcomes of HIV positive and negative recipients[J]. Ann Thorac Surg, 2021, 111(5): 1465-1471. DOI: 10.1016/j.athoracsur.2020.06.120.
[24]	LAM C, LANDRY S, MOUSSA G, et al. Pharmacotherapeutic interventions in people living with HIV undergoing solid organ transplantation: a scoping review[J]. Transplant Direct, 2023, 9(2): e1441. DOI: 10.1097/TXD.0000000000001441.
[25]	BLUMBERG EA, ROGERS CC, American Society of Transplantation Infectious Diseases Community of Practice. Solid organ transplantation in the HIV-infected patient: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13499. DOI: 10.1111/ctr.13499.
[26]	MAMATIS JE, PELLIZZARI-DELANO IE, GALLARDO-FLORES CE, et al. Emerging roles of cyclophilin A in regulating viral cloaking[J]. Front Microbiol, 2022, 13: 828078. DOI: 10.3389/fmicb.2022.828078.
[27]	HAN J, LEE MK, JANG Y, et al. Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents[J]. Drug Discov Today, 2022, 27(7): 1895-1912. DOI: 10.1016/j.drudis.2022.05.016.
[28]	GATHOGO E, HARBER M, BHAGANI S, et al. Impact of tacrolimus compared with cyclosporin on the incidence of acute allograft rejection in human immunodeficiency virus-positive kidney transplant recipients[J]. Transplantation, 2016, 100(4): 871-878. DOI: 10.1097/TP.0000000000000879.
[29]	VAN MAARSEVEEN EM, ROGERS CC, TROFE-CLARK J, et al. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review[J]. AIDS Patient Care STDS, 2012, 26(10): 568-581. DOI: 10.1089/apc.2012.0169.
[30]	HHS. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents 2011[EB/OL]. [2024-01-07].https://health.gov/healthypeople/tools-action/browse-evidence-based-resources/guidelines-use-antiretroviral-agents-adults-and-adolescents-living-hiv.
[31]	CRATER JM, NIXON DF, FURLER O'BRIEN RL. HIV-1 replication and latency are balanced by mTOR-driven cell metabolism[J]. Front Cell Infect Microbiol, 2022, 12: 1068436. DOI: 10.3389/fcimb.2022.1068436.
[32]	VARCO-MERTH BD, BRANTLEY W, MARENCO A, et al. Rapamycin limits CD4⁺ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapy[J]. J Clin Invest, 2022, 132(10): e156063. DOI: 10.1172/JCI156063.
[33]	PLANAS D, PAGLIUZZA A, PONTE R, et al. LILAC pilot study: effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy[J]. EBioMedicine, 2021, 65: 103270. DOI: 10.1016/j.ebiom.2021.103270.
[34]	HENRICH TJ, SCHREINER C, CAMERON C, et al. Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: a prospective study[J]. Am J Transplant, 2021, 21(5): 1765-1779. DOI: 10.1111/ajt.16244.
[35]	MALAT GE, RANGANNA KM, SIKALAS N, et al. High frequency of rejections in HIV-positive recipients of kidney transplantation: a single center prospective trial[J]. Transplantation, 2012, 94(10): 1020-1024. DOI: 10.1097/TP.0b013e31826c3947.
[36]	LOCKE JE, JAMES NT, MANNON RB, et al. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients[J]. Transplantation, 2014, 97(4): 446-450. DOI: 10.1097/01.TP.0000436905.54640.8c.
[37]	WERBEL WA, BAE S, YU S, et al. Early steroid withdrawal in HIV-infected kidney transplant recipients: utilization and outcomes[J]. Am J Transplant, 2021, 21(2): 717-726. DOI: 10.1111/ajt.16195.
[38]	SANTEUSANIO A, BHANSALI A, DE BOCCARDO G, et al. Conversion to belatacept maintenance immunosuppression in HIV-positive kidney transplant recipients[J]. Clin Transplant, 2020, 34(10): e14041. DOI: 10.1111/ctr.14041.
[39]	EL SAKHAWI K, MELICA G, SCEMLA A, et al. Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients[J]. Clin Kidney J, 2020, 14(8): 1908-1914. DOI: 10.1093/ckj/sfaa231.